128 related articles for article (PubMed ID: 6629320)
1. Determinants of drug disposition in patients with cirrhosis.
Huet PM; Villeneuve JP
Hepatology; 1983; 3(6):913-8. PubMed ID: 6629320
[TBL] [Abstract][Full Text] [Related]
2. Effect of portacaval shunt on drug disposition in patients with cirrhosis.
Pomier-Layrargues G; Huet PM; Villeneuve JP; Marleau D
Gastroenterology; 1986 Jul; 91(1):163-7. PubMed ID: 3710065
[TBL] [Abstract][Full Text] [Related]
3. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics.
Huet PM; Lelorier J
Clin Pharmacol Ther; 1980 Aug; 28(2):208-15. PubMed ID: 7398188
[TBL] [Abstract][Full Text] [Related]
4. Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension.
Berzigotti A; Reverter E; García-Criado A; Abraldes JG; Cerini F; García-Pagán JC; Bosch J
J Hepatol; 2013 Oct; 59(4):717-22. PubMed ID: 23669282
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of indocyanine green and lidocaine kinetics for survival and chronic hepatic encephalopathy in cirrhotic patients following elective end-to-side portacaval shunt.
Pomier-Layrargues G; Huet PM; Infante-Rivard C; Villeneuve JP; Marleau D; Duguay L; Tanguay S; Lavoie P
Hepatology; 1988; 8(6):1506-10. PubMed ID: 3192163
[TBL] [Abstract][Full Text] [Related]
6. Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis.
Colli A; Buccino G; Cocciolo M; Parravicini R; Scaltrini G
Clin Pharmacol Ther; 1988 Dec; 44(6):642-9. PubMed ID: 3197365
[TBL] [Abstract][Full Text] [Related]
7. Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease.
Møller S; la Cour Sibbesen E; Madsen JL; Bendtsen F
J Gastroenterol Hepatol; 2019 Jun; 34(6):1093-1099. PubMed ID: 30221390
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatic vein, umbilicoportal vein, and superior mesenteric artery catheterization in portal hypertension: estimation of the portal fraction of total hepatic blood flow in cirrhotic patients.
Huet PM; Lavoie P; Légaré A; Viallet A
Yale J Biol Med; 1975 Mar; 48(1):55-66. PubMed ID: 1130101
[TBL] [Abstract][Full Text] [Related]
9. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green.
Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
Clin Pharmacol Ther; 1976 Sep; 20(3):290-9. PubMed ID: 954351
[TBL] [Abstract][Full Text] [Related]
10. Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.
Møller S; Henriksen JH; Sjöstedt S; Bendtsen F
J Gastroenterol Hepatol; 2022 Apr; 37(4):692-699. PubMed ID: 35016257
[TBL] [Abstract][Full Text] [Related]
11. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis.
Pind ML; Bendtsen F; Kallemose T; Møller S
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):948-54. PubMed ID: 27172450
[TBL] [Abstract][Full Text] [Related]
12. Hepatic blood flow measurements and indocyanine green kinetics in a chronic dog model.
Skerjanec A; O'Brien DW; Tam TK
Pharm Res; 1994 Nov; 11(11):1511-5. PubMed ID: 7870662
[TBL] [Abstract][Full Text] [Related]
13. Functional and non-functional liver blood flow in patients with liver cirrhosis measured by indocyanine green.
Perlik F; Janku I; Jedlicka J
Methods Find Exp Clin Pharmacol; 1992; 14(6):459-64. PubMed ID: 1469955
[TBL] [Abstract][Full Text] [Related]
14. Lidocaine kinetics predicted by indocyanine green clearance.
Zito RA; Reid PR
N Engl J Med; 1978 May; 298(21):1160-3. PubMed ID: 651945
[TBL] [Abstract][Full Text] [Related]
15. Effect of liver blood flow and function on hepatic indocyanine green clearance measured directly in a cirrhotic animal model.
Jiao LR; El-Desoky AA; Seifalian AM; Habib N; Davidson BR
Br J Surg; 2000 May; 87(5):568-74. PubMed ID: 10792311
[TBL] [Abstract][Full Text] [Related]
16. Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis.
Merkel C; Bolognesi M; Finucci GF; Angeli P; Caregaro L; Rondana M; Gatta A
J Hepatol; 1989 Jul; 9(1):16-22. PubMed ID: 2768794
[TBL] [Abstract][Full Text] [Related]
17. Effect of cimetidine on the hepatic extraction of indocyanine green, the portal pressure and the systemic circulation in patients with cirrhosis of the liver.
Herz R; Rössle M; Bonzel T; Keller E; Gerok W
Klin Wochenschr; 1984 Aug; 62(16):759-64. PubMed ID: 6482311
[TBL] [Abstract][Full Text] [Related]
18. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
[TBL] [Abstract][Full Text] [Related]
19. Extraction of 125I-albumin microaggregates from portal blood. An index of functional portal blood supply in cirrhotics.
Huet PM; Marleau D; Lavoie P; Viallet A
Gastroenterology; 1976 Jan; 70(1):74-81. PubMed ID: 1245287
[TBL] [Abstract][Full Text] [Related]
20. Lidocaine kinetics: relationships between early lidocaine kinetics and indocyanine green clearance.
Zito RA; Reid PR
J Clin Pharmacol; 1981; 21(2):100-5. PubMed ID: 7229115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
